Abstract
The biological effects of N-( phosphonacetyl)- l - aspartate (PALA) and 5-fluorouracil (5-FU) were examined singly, and in combination, on the growth of a human mammary carcinoma (MDA) cell line in culture. All combinations of 5-FU (2.5 × 10 −7 to 1.5 × 10 −5M) and PALA (6.0 × 10 −5 to 3.6 × 10 −3 M) resulted in synergistic inhibition of cell growth as revealed by a 50 per cent isobologram.To examine the biochemical basis for the synergism, measurements of the incorporation of [ 3H]-5-FU into total non-poly(A)- and poly(A)-RNA, and of the simultaneous incorporation of [ 14C]deoxyguanosine and [ 3H]deoxyuridine into DNA, were determined. The combination of 3.7 × 10 −5M PALA and 1 × 10 −6 M 5-FU produced 65–85 per cent inhibition of cell growth after continuous treatment for 13 days. Treatment of the cells for 3 or 24 hr with the same drug regimen produced approximately a 170 per cent increase in the incorporation of 1 × 10 −6M [ 3H]-5-FU into poly(A)RNA in comparison to [ 3H]-5-FU treatment alone; exposure for 24 hr to 3.7 × 10 −5 M PALA and 1 × 10 −6 M [ 3H]-5-FU resulted in a 285 per cent increase in the incorporation of [ 3H]-5-FU into non-poly(A)RNA. The incorporation of either [ 14C]deoxyguanosine or [ 3H]deoxyuridine into DNA was not inhibited by this drug regimen; however, the incorporation of [ 3H]deoxyuridine into DNA was elevated significantly upon 12 or 24 hr of exposure to PALA alone. PALA and 5-FU treatment resulted in a 75 per cent reduction in the concentration of UTP and no change in the concentration of 5-fluorouridine-5′triphosphate 5-FUTP) versus 5-FU treatment alone. Thus, the proportion of 5-FUTP in the total 5FUTP + UTP pool was enhanced more than 3-fold by the combination regimen. These results indicate that the synergistic effect of the combination of PALA and 5-FU on the growth of MDA cells correlates with an increased proportion of 5-FUTP in the pyrimidine nucleotide pool and, consequently, with an enhanced incorporation of 5-FU into RNA, but not with inhibition of DNA synthesis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.